Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 2Withdrawn 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1

Conditions

Pancreatic Neoplasms 26Carcinoma, Non-Small-Cell Lung 14Breast Neoplasms 14Neoplasm Metastasis 7Triple Negative Breast Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Neoplasms 3Stomach Neoplasms 2Ovarian Neoplasms 2Metastatic Pancreatic Ductal Adenocarcinoma 2Lung Neoplasms 2Inflammatory Breast Neoplasms 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Unresectable Biliary Tract Cancer 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thromboembolism 1TNBC 1Sarcoma 1Peritoneal Neoplasms 1Oropharyngeal Neoplasms 1Non-small Cell Lung Cancer Metastatic 1Mouth Neoplasms 1Locally Advanced or Metastatic Solid Tumours 1Locally Advanced Unresectable Pancreatic Cancer Treated With Chemoradiotherapy 1Lip Neoplasms 1Laryngeal Neoplasms 1Head and Neck Neoplasms 1

Interventions

pembrolizumab 15Nivolumab 10avelumab 9atezolizumab 8Gemcitabine 8Cisplatin 8Magnetic Resonance Spectroscopy 6durvalumab 5Specimen Handling 5Docetaxel 5Carboplatin 5Paclitaxel 4Ipilimumab 4tislelizumab 3sacituzumab govitecan 3enfortumab vedotin 3Taxes 3Pemetrexed 3Mitomycin 3eribulin 2erdafitinib 2cabozantinib 2Doxorubicin 2CTLA-4 Antigen 2ALT-803 2zimberelimab 1veliparib 1urelumab 1tazemetostat 1spartalizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Carcinoma, Transitional Cell × 130-nm albumin-bound paclitaxel × Clear all
NCT05867121 2026-04-27

A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010

Genentech, Inc.

Phase 1 Active not recruiting
102 enrolled
GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡